AU2013337808B2 - Erythroferrone and ERFE polypeptides and methods of regulating iron metabolism - Google Patents

Erythroferrone and ERFE polypeptides and methods of regulating iron metabolism Download PDF

Info

Publication number
AU2013337808B2
AU2013337808B2 AU2013337808A AU2013337808A AU2013337808B2 AU 2013337808 B2 AU2013337808 B2 AU 2013337808B2 AU 2013337808 A AU2013337808 A AU 2013337808A AU 2013337808 A AU2013337808 A AU 2013337808A AU 2013337808 B2 AU2013337808 B2 AU 2013337808B2
Authority
AU
Australia
Prior art keywords
iron
erfe
hepcidin
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013337808A
Other languages
English (en)
Other versions
AU2013337808A1 (en
Inventor
Tomas Ganz
Leon KAUTZ
Elizabeta Nemeth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2013337808A1 publication Critical patent/AU2013337808A1/en
Application granted granted Critical
Publication of AU2013337808B2 publication Critical patent/AU2013337808B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
AU2013337808A 2012-11-01 2013-10-31 Erythroferrone and ERFE polypeptides and methods of regulating iron metabolism Ceased AU2013337808B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721322P 2012-11-01 2012-11-01
US61/721,322 2012-11-01
PCT/US2013/067771 WO2014071015A1 (en) 2012-11-01 2013-10-31 Erythroferrone and erfe polypeptides and methods of regulating iron metabolism

Publications (2)

Publication Number Publication Date
AU2013337808A1 AU2013337808A1 (en) 2015-05-14
AU2013337808B2 true AU2013337808B2 (en) 2017-12-21

Family

ID=50628048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013337808A Ceased AU2013337808B2 (en) 2012-11-01 2013-10-31 Erythroferrone and ERFE polypeptides and methods of regulating iron metabolism

Country Status (11)

Country Link
US (2) US20160122409A1 (enExample)
EP (1) EP2914619B1 (enExample)
JP (1) JP6501362B2 (enExample)
KR (1) KR102186218B1 (enExample)
CN (1) CN104854130A (enExample)
AU (1) AU2013337808B2 (enExample)
BR (1) BR112015009954A2 (enExample)
CA (1) CA2890040A1 (enExample)
ES (1) ES2731609T3 (enExample)
RU (1) RU2684216C2 (enExample)
WO (1) WO2014071015A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3448405B1 (en) 2016-04-27 2024-07-03 Vladimir Badmaev Method maintaining iron homeostasis with shogaols
US20190284274A1 (en) * 2016-08-05 2019-09-19 Silarus Therapeutics, Inc. Erfe specific antibodies compositions and methods of use
EP3519432A1 (en) * 2016-10-03 2019-08-07 Silarus Therapeutics, Inc. Erfe fusion polypeptides compositions and methods of use
IL269318B2 (en) * 2017-03-13 2024-10-01 Intrinsic Lifesciences Llc ANTIBODIES TO HUMAN ERYTHROFERRONE AND USES THEREOF
EP3628006A4 (en) * 2017-05-16 2021-07-21 Generos Biopharma Ltd. COMPOSITIONS AND METHODS OF TREATMENT FOR RHEUMATOID ARTHRITIS
US11255865B2 (en) 2017-06-06 2022-02-22 The Regents Of The University Of California Immunoassay for human erythroferrone
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
WO2019212364A1 (en) * 2018-05-01 2019-11-07 Christopher Joseph Pemberton Test for heart failure
US20210196823A1 (en) * 2018-06-08 2021-07-01 Pfizer Inc. Methods of Treating Metabolic Disease
US20220119516A1 (en) * 2019-01-16 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2024170505A1 (en) 2023-02-13 2024-08-22 Institut National de la Santé et de la Recherche Médicale Methods of treatment of iron overload associated diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046073A2 (en) * 2004-10-28 2006-05-04 Ares Trading S.A. C1q related protein
WO2013112663A1 (en) * 2012-01-26 2013-08-01 The Johns Hopkins University Myonectin (ctrp15), compositions comprising same, and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749713B2 (en) * 2002-11-19 2010-07-06 Hasan Kulaksiz Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
CA2597925A1 (en) * 2005-02-16 2006-08-24 The General Hospital Corporation Use of a human hemojuvelin product to regulate hepcidin-mediated iron metabolism
TW201206954A (en) * 2007-02-02 2012-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
GB0818273D0 (en) * 2008-10-06 2008-11-12 Cambridge Entpr Ltd Modulation of cellular activity and differentiation
WO2010065815A2 (en) * 2008-12-05 2010-06-10 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046073A2 (en) * 2004-10-28 2006-05-04 Ares Trading S.A. C1q related protein
WO2013112663A1 (en) * 2012-01-26 2013-08-01 The Johns Hopkins University Myonectin (ctrp15), compositions comprising same, and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GenBank Accession Number AAH56923, 18 March 2009 *
GenBank Accession Number XP_002813099, 17 July 2012 *

Also Published As

Publication number Publication date
KR20150077471A (ko) 2015-07-07
US20160122409A1 (en) 2016-05-05
JP6501362B2 (ja) 2019-04-17
CN104854130A (zh) 2015-08-19
AU2013337808A1 (en) 2015-05-14
EP2914619A1 (en) 2015-09-09
CA2890040A1 (en) 2014-05-08
JP2015536337A (ja) 2015-12-21
BR112015009954A2 (pt) 2017-08-22
KR102186218B1 (ko) 2020-12-03
ES2731609T3 (es) 2019-11-18
EP2914619A4 (en) 2016-05-11
US20180355008A1 (en) 2018-12-13
RU2684216C2 (ru) 2019-04-04
WO2014071015A1 (en) 2014-05-08
RU2015120601A (ru) 2016-12-20
EP2914619B1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
AU2013337808B2 (en) Erythroferrone and ERFE polypeptides and methods of regulating iron metabolism
Zhong et al. Energy stress modulation of AMPK/FoxO3 signaling inhibits mitochondria-associated ferroptosis
Kim et al. TFEB–GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response
Zeng et al. Lysine-specific demethylase 1 promotes brown adipose tissue thermogenesis via repressing glucocorticoid activation
Babitt et al. The molecular pathogenesis of hereditary hemochromatosis
Piperno et al. Hepcidin modulation in human diseases: from research to clinic
Kautz et al. Identification of erythroferrone as an erythroid regulator of iron metabolism
Marionneau et al. The sodium channel accessory subunit Navβ1 regulates neuronal excitability through modulation of repolarizing voltage-gated K+ channels
Bin et al. Molecular pathogenesis of Spondylocheirodysplastic Ehlers‐Danlos syndrome caused by mutant ZIP13 proteins
Cho et al. STK3/STK4 signalling in adipocytes regulates mitophagy and energy expenditure
Yue et al. Yap1 modulates cardiomyocyte hypertrophy via impaired mitochondrial biogenesis in response to chronic mechanical stress overload
Yang et al. Phospho-Ser727 triggers a multistep inactivation of STAT3 by rapid dissociation of pY705–SH2 through C-terminal tail modulation
Yang et al. Receptor for activated C kinase 1 (RACK1) inhibits function of transient receptor potential (TRP)-type channel Pkd2L1 through physical interaction
Dearth et al. Expression and function of CCAAT/enhancer binding proteinβ (C/EBPβ) LAP and LIP isoforms in mouse mammary gland, tumors and cultured mammary epithelial cells
Chen et al. Abnormal iron uptake and liver cancer
An et al. Soluble LILRA3 promotes neurite outgrowth and synapses formation through a high-affinity interaction with Nogo 66
Ito et al. Pallidin is a novel interacting protein for cytohesin‐2 and regulates the early endosomal pathway and dendritic formation in neurons
Smith et al. α-Synuclein is the major platelet isoform but is dispensable for activation, secretion, and thrombosis
Chen et al. IKKα-STAT3-S727 axis: A novel mechanism in DOX-induced cardiomyopathy
Jiang et al. ZFYVE21 promotes endothelial nitric oxide signaling and vascular barrier function in the kidney during aging
AU2012272550B2 (en) Prevention and treatment of acute inflammatory conditions
Feng et al. Caveolin-1 directly interacts with UT-A1 urea transporter: the role of caveolae/lipid rafts in UT-A1 regulation at the cell membrane
Ramshaw et al. The Shc-binding site of the βc subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis
Wang et al. Peptidase inhibitor 16 promotes inflammatory arthritis by suppressing Foxp3 expression via regulating K48-linked ubiquitin degradation Bmi-1 in regulatory T cells
Kamanna et al. Low density lipoproteins transactivate EGF receptor: role in mesangial cell proliferation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired